Recombinant Human Hepatocyte Growth Factor (HGF) Protein (His), Active

Beta LifeScience SKU/CAT #: BLC-05961P
Greater than 95% as determined by SDS-PAGE.
Greater than 95% as determined by SDS-PAGE.

Recombinant Human Hepatocyte Growth Factor (HGF) Protein (His), Active

Beta LifeScience SKU/CAT #: BLC-05961P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Hepatocyte Growth Factor (HGF) Protein (His), Active is produced by our Mammalian cell expression system. This is a full length protein.
Purity Greater than 95% as determined by SDS-PAGE.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity The ED50 as determined by its ability to induce IL-11 secretion by Saos-2 human osteosarcoma cells is less than 10 ng/ml.
Uniprotkb P14210
Target Symbol HGF
Synonyms DFNB39; F TCF; Fibroblast derived tumor cytotoxic factor; Hepatocyte growth factor (hepapoietin A; scatter factor); Hepatocyte growth factor; Hepatocyte growth factor beta chain; Hepatocyte growth factor precursor; Hepatopoietin A; Hepatopoietin-A; Hgf; HGF_HUMAN; HGFB; HPTA; Lung fibroblast derived mitogen; OTTHUMP00000161349; OTTHUMP00000206710; OTTHUMP00000206711; OTTHUMP00000206712; OTTHUMP00000206713; OTTHUMP00000206730; Scatter factor; SF
Species Homo sapiens (Human)
Expression System Mammalian cell
Tag C-6His
Complete Sequence QRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVECMTCNGESYRGLMDHTESGKICQRWDHQTPHRHKFLPERYPDKGFDDNYCRNPDGQPRPWCYTLDPHTRWEYCAIKTCADNTMNDTDVPLETTECIQGQGEGYRGTVNTIWNGIPCQRWDSQYPHEHDMTPENFKCKDLRENYCRNPDGSESPWCFTTDPNIRVGYCSQIPNCDMSHGQDCYRGNGKNYMGNLSQTRSGLTCSMWDKNMEDLHRHIFWEPDASKLNENYCRNPDDDAHGPWCYTGNPLIPWDYCPISRCEGDTTPTIVNLDHPVISCAKTKQLRVVNGIPTRTNIGWMVSLRYRNKHICGGSLIKESWVLTARQCFPSRDLKDYEAWLGIHDVHGRGDEKCKQVLNVSQLVYGPEGSDLVLMKLARPAVLDDFVSTIDLPNYGCTIPEKTSCSVYGWGYTGLINYDGLLRVAHLYIMGNEKCSQHHRGKVTLNESEICAGAEKIGSGPCEGDYGGPLVCEQHKMRMVLGVIVPGRGCAIPNRPGIFVRVAYYAKWIHKIILTYKVPQS
Expression Range 32-728aa
Protein Length Full Length of Mature Protein
Mol. Weight 79.7 kDa
Research Area Cancer
Form Liquid or Lyophilized powder
Buffer Lyophilized from a 0.2 μm Filtered 20 mM Tris-HCl, 500 mM NaCl, pH 8.0
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.

Target Details

Target Function Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization.
Protein Families Peptidase S1 family, Plasminogen subfamily
Database References
Associated Diseases Deafness, autosomal recessive, 39 (DFNB39)

Gene Functions References

  1. miR-449a suppresses hepatocellular carcinoma tumorigenesis by down-regulating activity in the c-Met/ERK pathway. PMID: 30108016
  2. widely stained in sclerosing stromal tumours of the ovary PMID: 29433373
  3. This novel study, in HIV-positive, preeclampsia, and normotensive pregnancies, demonstrates that HGF was two-fold higher in conducting compared to exchange villi irrespective of the pregnancy type. HIV infection does not influence HGF expression within the conducting and exchange villi. PMID: 29886319
  4. CAFderived HGF promotes angiogenesis. PMID: 29917165
  5. These results suggest that gastric cancer progression is not associated with a unique signaling pathway and that a feedback loop may exist between the HGF/c-Met and Notch1 signaling pathways, which may result in therapeutic resistance. PMID: 29781036
  6. a higher HGF serum level during hemodialysis treatment is associated with a slower loss of residual renal function PMID: 29227979
  7. prolonged treatment of single HGF/c-Met or Hh inhibitor leads to resistance to these single inhibitors, likely because the single c-Met treatment leads to enhanced expression of Shh, and vice versa. Targeting both the HGF/c-Met and Hh pathways simultaneously overcame the resistance to the single-inhibitor treatment and led to a more potent antitumor effect in combination with the chemotherapy treatment. PMID: 28864680
  8. TGF-beta negatively controls the HGF/c-MET pathway by regulating of stemness in glioblastoma. PMID: 29238047
  9. Reduction of fibroblast size upregulates HGF expression, which in turn contributes to loss of collagen, a prominent feature of aged skin. PMID: 28826691
  10. Results of our present study suggest that both IL-6 and HGF derived from Cancer-associated fibroblasts (CAFs)could contribute to the intratumoral androgen metabolism in ER-negative breast carcinoma patients. PMID: 28831645
  11. Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease. Review. PMID: 12201209
  12. this study shows that decidual NK cells facilitate the interaction between trophoblastic and endothelial cells via VEGF-C and HGF PMID: 28653669
  13. We identify HGF, acting through the c-Met receptor, as the key polarity-inducing morphogen, which acts to activate b1-integrin-dependent adhesion. HGF and ECM-derived integrin signals co-operate via a c-Src-dependent inhibition of the RhoA-ROCK1 signalling pathway via p190A RhoGAP. PMID: 28888686
  14. High glucose activated Met receptor in HK2 cells independently of HGF, via induction of integrin a5b1 and downstream signaling. This mode of Met activation was associated with tubular cell damage and apoptosis and it may represent a novel pathogenic mechanism and a treatment target in diabetic nephropathy. PMID: 28819999
  15. results show that HGF was involved in regulating Chk1 phosphorylation, and further demonstrate that AKT activity was responsible for this HGF-induced Chk1 phosphorylation. PMID: 28573382
  16. Lymph node metastasis is strongly associated with expression status of HGF and CD133 at the deep invasive front, suggesting the usefulness of these proteins as independent predictive markers of lymph node metastasis in early gastric cancer. PMID: 28595915
  17. EGF-mediated lysosome trafficking, protease secretion, and invasion is regulated by the activity of p38 mitogen activated protein kinase (MAPK) and sodium hydrogen exchangers (NHEs). Interestingly, EGF stimulates anterograde lysosome trafficking through a different mechanism than previously reported for HGF, suggesting that there are redundant signaling pathways that control lysosome positioning PMID: 28978320
  18. HGF/c-MET pathway mediates VEGFR inhibitor resistance and vascular remodeling in NSCLC. PMID: 28559461
  19. We also propose that full-length HGF and HGF-NK1 convey desirable wound healing properties, whilst fibroblasts preferentially expressing more HGF-NK2 readily undergo TGF-beta-driven differentiation into myofibroblasts. PMID: 28837064
  20. In conclusion, these findings indicate that CMs derived from primary culture of NPC fractions of BA liver contain a large amount of active HGF, which may activate hepatic stem/progenitor cells and promote the appearance of hepatocyte-like cells or their clusters through HGF/c-Met signaling. PMID: 28364348
  21. Oxidative stress contributes to HGF-dependent pro-senescence activity of ovarian cancer cells. PMID: 28652056
  22. These results hold promise that dual targeting of HGF and MET by combining extracellular ligand inhibitors with intracellular MET TKIs could be an effective intervention strategy for cancer patients who have acquired resistance that is dependent on total MET protein. PMID: 28341789
  23. cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa. PMID: 28013036
  24. The results suggested that HGF may inhibit TEMT by inhibiting AngII through the JAK2/STAT3 signaling pathway in HK2 cells and HGF may prevent apoptosis induced by AngII. The present study provides a basis for understanding the mechanisms involved in the inhibition of TEMT by HGF, which requires further investigation PMID: 28447719
  25. The identification of novel small-molecule inhibitors of microtubule polymerization highlights the role of the microtubule cytoskeleton in HGF-induced epithelial scattering. PMID: 27245142
  26. miRNA-200a expression was inverse correlation with HGF expression in stromal fibroblasts. High miRNA-200a and low HGF expression in stromal fibroblasts may predict a good prognosis in patients with non-small cell lung cancer. PMID: 27374174
  27. Activation of proHGF by St14 induces mouse embryonic stem cell differentiation. PMID: 27316827
  28. Study shows that Met and HGF have a multi-factorial relationship to the biology and outcome of breast cancer, influenced by gene copy number and protein expression, activation status, stromal environment, and cellular localisation. PMID: 27175600
  29. These results reveal the effect of HGF on the distinct pathways of eosinophil secretory functions and also provide novel insights into the role of HGF in the pathogenesis of allergic inflammation. PMID: 27552115
  30. The hepatocyte growth factor (HGF)-MET receptor tyrosine kinase signaling pathway PMID: 26822708
  31. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2 PMID: 28358369
  32. High HGF expression is associated with castration-resistant progression in androgen dependent metastatic prostate cancer. PMID: 27599544
  33. miR-26a/mir-26b could suppress tumorigenesis and angiogenesis by targeting the HGF-VEGF axis, and could serve as a potential treatment modality for targeted therapy in the clinical treatment of gastric cancer. PMID: 28738343
  34. Which control critical events for colonization such as HGF/Met axis and Wwox, as therapy of bone metastasis. PMID: 28151481
  35. Data suggest that HGF, IL-20, and IL-22 in the serum and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients before chemotherapy may be a prognostic of cancer progression. PMID: 27573644
  36. Studies indicate that the over-expression of hepatocyte growth factor (HGF) is valuable in colorectal cancer (CRC) prognosis. PMID: 28423584
  37. These results establish HGF/C-Met as a central organizing signal in blood vessel-directed tumor cell migration in vivo and highlight a promising role for C-Met inhibitors in blocking tumor cell streaming and metastasis in vivo, and for use in human trials. PMID: 27893712
  38. Furthermore, activation of HGF/Met signaling increased the expression and transcriptional activity of FOXM1, and the cross talk between FOXM1 and HGF/Met signaling promoted pancreatic ductal adenocarcinoma (PDA)growth and resistance to Met inhibition PMID: 26876216
  39. These data suggest that paxillin appears to influence major cell functions in a diverse range of prostate and breast cancer models. The responsiveness of cells to environmental factors such as HGF or BME may be influenced by paxillin status, although this seems to be dependent on cell type PMID: 28739717
  40. Fibronectin and Hepatocyte Growth Factor were shown to be produced by lung fibroblasts and, furthermore, to enhance malignant pleural mesothelioma cell migration and invasion PMID: 28476806
  41. Glioblastoma patients with high expression of hepatocyte growth factor or unmethylated O(6)-methylguanine-DNA methyltransferase may benefit from onartuzumab plus bevacizumab chemotherapy. PMID: 27918718
  42. Plasma levels of HGF in PAH patients with mild disease were significantly higher than those in healthy controls, suggesting that plasma HGF has potential utility as a diagnostic biomarker for early PAH. PMID: 27342109
  43. Blood HGF was significantly higher in chronic hepatitis C patients with liver fibrosis compared to those without fibrosis. PMID: 27930387
  44. In summary, a decrease in VEGF-A and an increase in sVEGFR1 during chemotherapy and bevacizumab exposure can contribute to both chemotherapy (due to c-MET/b-catenin activation) and bevacizumab (due to low VEGF requirements) resistance. Because HGF levels decrease also during acquired resistance, alternative strategies to HGF-ligand inhibition should be investigated PMID: 28621236
  45. We found the roles of hepatocyte growth factor (HGF) signaling in stria vascularis development for the first time and that lack of HGF signaling in the inner ear leads to profound hearing loss in the mouse. Our findings reveal a novel mechanism that may underlie human deafness DFNB39 and DFNB97. Our findings reveal an additional example of context-dependent c-MET signaling diversity, required here for proper cellular inva PMID: 27488639
  46. Either upregulating miR-182 in retinal pigment epithelial cells or downregulating c-Met expression reduced HGF/SF-induced rises in both retinal pigment epithelial cells proliferation and chemotaxis through declines in Akt activation. PMID: 27936146
  47. Enzyme-linked immunosorbent assay was used to detect the levels of chemokine (C-X-C motif) ligand 12, chemokine (C-X-C motif) ligand 7, hepatocyte growth factor, and fibroblast growth factor 1 in the supernatants of the laryngeal squamous cell carcinoma and control cells. PMID: 28475003
  48. Potential immune markers, including interleukin 1 receptor antagonist, interferon gamma-inducible protein 10, hepatocyte growth factor, soluble p75 tumor necrosis factor alpha receptor, vascular cell adhesion molecule 1, and matrix metalloproteinase 2, were significantly associated with significant plasma leakage during Dengue virus infection. PMID: 28077582
  49. Results indicated that HGF may promote angiogenesis by not only increasing the expression of VEGF but also by decreasing the expression of an angiostatic chemokine, CXCL10 in keratinocytes. PMID: 27718226
  50. overexpression of HGF resulted in resistance to c-MET tyrosine kinase inhibitors through an autocrine manner in gastric cancer cells PMID: 28314274

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed